actinium pharmaceuticals inc (ATNM) Key Developments
Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program
Oct 27 14
Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.
Actinium Pharmaceuticals, Inc. - Special Call
Oct 14 14
To discuss on emerging therapies for Acute Myeloid Leukemia
Actinium Pharmaceuticals, Inc. Presents at RedChip Global Online CEO Conference, Oct-15-2014 11:00 AM
Oct 6 14
Actinium Pharmaceuticals, Inc. Presents at RedChip Global Online CEO Conference, Oct-15-2014 11:00 AM.
Actinium Pharmaceuticals, Inc Appoints Richard E. Champlin to Scientific Advisory Board
Sep 10 14
Actinium Pharmaceuticals, Inc. announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the company's radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine.
Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014
Sep 10 14
Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Sep-30-2014, Dragan Cicic, Chief Operating Officer and Chief Medical Officer, Sandesh C. Seth, Chairman and Member of Compensation Committee.